Definition
Succinylacetone is an organic compound that serves as a toxic metabolic intermediate in the catabolism of the amino acid tyrosine. It is most prominently associated with hereditary tyrosinemia type I, where its accumulation contributes to hepatic, renal, and neurologic pathology.
Overview
In the normal degradation pathway of tyrosine, fumarylacetoacetate is hydrolyzed by the enzyme fumarylacetoacetate hydrolase (FAH) to yield fumarate and acetoacetate. When FAH is deficient, as in tyrosinemia type I, fumarylacetoacetate accumulates and undergoes non‑enzymatic decarboxylation to form succinylacetone. The presence of succinylacetone in plasma, urine, or dried blood spots is a highly specific biomarker for the disease and is routinely measured in newborn screening programs.
Succinylacetone exerts inhibitory effects on enzymes involved in heme biosynthesis, notably δ‑aminolevulinic acid dehydratase (ALAD) and porphobilinogen synthase, leading to secondary porphyria‑like manifestations. Its toxicity also includes DNA damage and oxidative stress, contributing to the liver failure observed in untreated patients.
Therapeutically, the drug nitisinone (NTBC) blocks an upstream step in tyrosine catabolism, preventing the formation of fumarylacetoacetate and consequently reducing succinylacetone levels. Monitoring succinylacetone concentrations is therefore essential for disease management and treatment efficacy assessment.
Etymology/Origin
The name “succinylacetone” derives from its structural relationship to succinic acid (a four‑carbon dicarboxylic acid) and acetone. The molecule can be viewed as a succinyl (–CH₂–CH₂–CO–) group attached to an acetyl (–CO–CH₃) moiety, reflecting the combination of these two fragments in its backbone.
Characteristics
| Property | Description |
|---|---|
| IUPAC name | 4‑oxopentanoic acid |
| Molecular formula | C₅H₈O₃ |
| Molecular weight | 116.11 g·mol⁻¹ |
| Physical state | White to off‑white crystalline solid |
| Melting point | Approximately 160–165 °C |
| Solubility | Highly soluble in water; also soluble in polar organic solvents (e.g., methanol, ethanol) |
| Stability | Stable under neutral conditions; decomposes slowly in strongly alkaline solutions |
| Spectral data | Exhibits characteristic infrared absorption bands for carbonyl (≈1700 cm⁻¹) and carboxylic acid groups; ^1H NMR shows signals for a terminal methyl, methylene protons, and a carboxylic proton (exchangeable) |
| Biological activity | Potent inhibitor of δ‑aminolevulinic acid dehydratase and porphobilinogen synthase; induces oxidative stress and DNA damage in vitro |
Related Topics
- Hereditary tyrosinemia type I – autosomal recessive disorder caused by FAH deficiency, leading to succinylacetone accumulation.
- Fumarylacetoacetate hydrolase (FAH) – enzyme whose loss of function initiates succinylacetone production.
- Nitisinone (NTBC) – pharmacologic inhibitor used to prevent succinylacetone formation in tyrosinemia type I.
- Porphyria – group of disorders of heme synthesis; succinylacetone‑induced inhibition of ALAD links it to porphyric symptoms.
- Newborn screening – programs commonly measure succinylacetone in dried blood spots to detect tyrosinemia type I early.
All information presented reflects current scientific consensus and established literature up to the knowledge cutoff date.